JP2003530432A5 - - Google Patents

Download PDF

Info

Publication number
JP2003530432A5
JP2003530432A5 JP2001576010A JP2001576010A JP2003530432A5 JP 2003530432 A5 JP2003530432 A5 JP 2003530432A5 JP 2001576010 A JP2001576010 A JP 2001576010A JP 2001576010 A JP2001576010 A JP 2001576010A JP 2003530432 A5 JP2003530432 A5 JP 2003530432A5
Authority
JP
Japan
Prior art keywords
kit
group
agent
derivative
analog
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001576010A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003530432A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/012484 external-priority patent/WO2001078709A2/en
Publication of JP2003530432A publication Critical patent/JP2003530432A/ja
Publication of JP2003530432A5 publication Critical patent/JP2003530432A5/ja
Pending legal-status Critical Current

Links

JP2001576010A 2000-04-12 2001-04-12 神経変性疾患の治療 Pending JP2003530432A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US19649700P 2000-04-12 2000-04-12
US60/196,497 2000-04-12
US21422100P 2000-06-23 2000-06-23
US60/214,221 2000-06-23
US24889000P 2000-11-15 2000-11-15
US60/248,890 2000-11-15
PCT/US2001/012484 WO2001078709A2 (en) 2000-04-12 2001-04-12 Treatment of neurodegenerative disease

Publications (2)

Publication Number Publication Date
JP2003530432A JP2003530432A (ja) 2003-10-14
JP2003530432A5 true JP2003530432A5 (https=) 2008-06-05

Family

ID=27393612

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001576010A Pending JP2003530432A (ja) 2000-04-12 2001-04-12 神経変性疾患の治療

Country Status (6)

Country Link
US (1) US20030060487A1 (https=)
EP (1) EP1328261A2 (https=)
JP (1) JP2003530432A (https=)
AU (1) AU2001253597A1 (https=)
CA (1) CA2404858A1 (https=)
WO (1) WO2001078709A2 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050148101A1 (en) * 1999-01-23 2005-07-07 Bamdad Cynthia C. Interaction of colloid-immobilized species with species on non-colloidal structures
WO2002029411A2 (en) 2000-10-03 2002-04-11 Minerva Biotechnologies Corporation Magnetic in situ dilution
US7054758B2 (en) 2001-01-30 2006-05-30 Sciona Limited Computer-assisted means for assessing lifestyle risk factors
AU2002326589B2 (en) * 2001-08-07 2008-06-05 University Of Delaware Compositions and methods for the prevention and treatment of Huntington's disease
US20040096880A1 (en) * 2001-08-07 2004-05-20 Kmiec Eric B. Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation
FR2828693B1 (fr) † 2001-08-14 2004-06-18 Exonhit Therapeutics Sa Nouvelle cible moleculaire de la neurotoxicite
JP2005507876A (ja) 2001-09-05 2005-03-24 ミナーバ バイオテクノロジーズ コーポレイション 癌を治療する組成物および方法
US20060280730A1 (en) * 2001-10-12 2006-12-14 Cedars-Sinai Medical Center Induction of apoptosis of malignant cells by activation of calcium-activated potassium channels
JP2006517674A (ja) 2002-12-20 2006-07-27 ミネルバ バイオテクノロジーズ コーポレーション ナノ粒子を含む光学デバイスおよび方法
EP1470818B1 (en) * 2003-04-25 2006-07-26 Neuro3D Use of piperazine phenothiazine derivatives in the manufacture of a medicament with neuroprotector and/or neurotrophic effects on cns and/or pns
FR2856595B1 (fr) * 2003-06-27 2008-05-30 Exonhit Therapeutics Sa Methodes et compositions pour le traitement de deficits cognitifs.
US20050059744A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
RU2416603C9 (ru) 2005-10-25 2012-06-20 Сионоги Энд Ко., Лтд. Производные аминодигидротиазина
WO2007120972A2 (en) * 2006-02-10 2007-10-25 University Of Virginia Patent Foundation Method to treat sickle cell disease
AU2007218217A1 (en) * 2006-02-24 2007-08-30 Axelar Ab Use of cyclolignans for the treatment of type 2 diabetes and as contraceptives
EP2147914B1 (en) 2007-04-24 2014-06-04 Shionogi&Co., Ltd. Aminodihydrothiazine derivatives substituted with cyclic groups
EP2151435A4 (en) 2007-04-24 2011-09-14 Shionogi & Co PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
WO2009005469A2 (en) * 2007-07-03 2009-01-08 David Erlinge The use of compounds such as pyridoxal derivatives for the treatment of diabetes or diseases associated with the metabolic syndrome
WO2009151098A1 (ja) 2008-06-13 2009-12-17 塩野義製薬株式会社 βセクレターゼ阻害作用を有する含硫黄複素環誘導体
CN102186841A (zh) 2008-10-22 2011-09-14 盐野义制药株式会社 具有bace1抑制活性的2-氨基嘧啶-4-酮及2-氨基吡啶衍生物
TWI488852B (zh) 2009-12-11 2015-06-21 Shionogi & Co 衍生物
US9662347B2 (en) * 2010-05-11 2017-05-30 Gachon University Of Industry-Academic Cooperation Foundation Method for inhibiting the induction of cell death by inhibiting the synthesis or secretion of age-albumin in cells of the mononuclear phagocyte system
US20120101167A1 (en) 2010-10-25 2012-04-26 Langham Maurice E Treatment of ocular and cerebral ischemia
JP5816630B2 (ja) 2010-10-29 2015-11-18 塩野義製薬株式会社 ナフチリジン誘導体
JP5766198B2 (ja) 2010-10-29 2015-08-19 塩野義製薬株式会社 縮合アミノジヒドロピリミジン誘導体
TW201247635A (en) 2011-04-26 2012-12-01 Shionogi & Co Oxazine derivatives and a pharmaceutical composition for inhibiting BAC1 containing them
JP6126531B2 (ja) * 2011-10-03 2017-05-10 国立研究開発法人国立長寿医療研究センター タウ凝集阻害剤
CN102381991A (zh) * 2011-10-22 2012-03-21 杭州福斯特药业有限公司 一种章胺盐酸盐的合成方法
JP2015512409A (ja) * 2012-03-26 2015-04-27 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク 脊髄性筋萎縮症用治療剤としての４−アミノピリジン
EP2912035A4 (en) 2012-10-24 2016-06-15 Shionogi & Co DERIVATIVES OF DIHYDROOXAZINE OR OXAZEPINE HAVING BACE1 INHIBITING ACTIVITY
US9907799B2 (en) 2013-04-02 2018-03-06 The Doshisha Tau aggregation inhibitor
EP3019865A4 (en) * 2013-07-12 2017-04-05 Immuneering Corporation Systems, methods, and environment for automated review of genomic data to identify downregulated and/or upregulated gene expression indicative of a disease or condition
US11648212B2 (en) * 2016-02-03 2023-05-16 Intelgenx Corp. Loxapine film oral dosage form
AU2017263657A1 (en) * 2016-05-13 2018-11-29 The Board Of Trustees Of The Leland Stanford Junior University Adrenergic receptor modulating compounds and methods of using the same
US20230395255A1 (en) * 2020-10-22 2023-12-07 Icahn School Of Medicine At Mount Sinai Methods for identifying and targeting the molecular subtypes of alzheimer's disease

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) * 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3832253A (en) * 1973-03-21 1974-08-27 Baxter Laboratories Inc Method of making an inflatable balloon catheter
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US5525727A (en) * 1982-05-18 1996-06-11 University Of Florida Brain-specific drug delivery
US4667014A (en) * 1983-03-07 1987-05-19 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4452775A (en) * 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
CA1200416A (en) * 1983-05-13 1986-02-11 Societe Des Produits Nestle S.A. Food process
US5075109A (en) * 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
DE3853758T2 (de) * 1987-10-05 1995-09-07 Yamanouchi Pharma Co Ltd Heterozyklische Spiroverbindungen und ihre Herstellung.
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
DE4023369A1 (de) * 1990-07-23 1992-01-30 Thomae Gmbh Dr K Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5338663A (en) * 1990-08-24 1994-08-16 President And Fellows Of Harvard College Method of identifying inhibitors of β-protein esterase activity
JPH04167172A (ja) * 1990-10-31 1992-06-15 Nec Corp ベクトルプロセッサ
US5614519A (en) * 1991-02-06 1997-03-25 Karl Thomae Gmbh (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5238942A (en) * 1991-05-10 1993-08-24 Merck & Co., Inc. Substituted quinazolinones bearing acidic functional groups as angiotensin ii antagonists
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5962463A (en) * 1992-10-09 1999-10-05 Massachusetts Institute Of Technology Methods of stimulating non-amyloidogenic processing of the amyloid precursor protein
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
IL112567A (en) * 1994-02-10 2000-02-29 Wyeth John & Brother Ltd Substituted quinolines their preparation and pharmaceutical compositions containing them
US5620850A (en) * 1994-09-26 1997-04-15 President And Fellows Of Harvard College Molecular recognition at surfaces derivatized with self-assembled monolayers
US5605911A (en) * 1995-01-31 1997-02-25 Washington University Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
WO1997048391A2 (en) * 1996-06-21 1997-12-24 Advanced Research And Technology Institute Methods and compositions comprising r-ibuprofen
AU4078997A (en) * 1996-08-22 1998-03-06 New York University Cholinesterase inhibitors for treatment of parkinson's disease
AU4031697A (en) * 1996-08-29 1998-03-19 Takeda Chemical Industries Ltd. Cyclic ether compounds as sodium channel modulators
US6184248B1 (en) * 1996-09-05 2001-02-06 Robert K. K. Lee Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
AU727611B2 (en) * 1996-12-12 2000-12-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Synthetic antisense oligodeoxynucleotides and pharmaceutical compositions containing them
FR2757161B1 (fr) * 1996-12-13 1999-03-12 Sanofi Sa Diphenylalkyl-tetrahydropyridines
WO1998027972A2 (en) * 1996-12-23 1998-07-02 Texas A & M University Anti-amyloidogenic agents
US6130221A (en) * 1997-03-05 2000-10-10 Nymox Corporation Pharmaceutical agents that impede the initiation and progression of primary and secondary DMS disruptions
US6514686B2 (en) * 1997-04-28 2003-02-04 The University Of British Columbia Method and composition for modulating amyloidosis
AU7260398A (en) * 1997-04-28 1998-11-24 University Of British Columbia, The Method and composition for modulating amyloidosis
ZA985765B (en) * 1997-07-02 1999-08-04 Merck & Co Inc Polymorphic form of a tachykinin receptor antagonist.
US6136559A (en) * 1998-10-07 2000-10-24 Ortho Pharmaceutical Corporation DNA encoding as human histamine receptor of the H3 subtype
US6586475B1 (en) * 1998-11-20 2003-07-01 Takeda Chemical Industries, Ltd. β-amyloid protein production/secretion inhibitors
EP1132372A3 (en) * 2000-03-06 2003-11-19 Solvias AG Bicyclic 1,3-aminoalcohols, d8-metal complexes and hydrogenation processes
WO2002029411A2 (en) * 2000-10-03 2002-04-11 Minerva Biotechnologies Corporation Magnetic in situ dilution
WO2002039999A2 (en) * 2000-11-15 2002-05-23 Minerva Biotechnologies Corporation Use of suramine, l-histidine, quisqualic acid or d-cycloserine for angiogenesis inhibition
EP1348034B1 (en) * 2000-11-15 2016-07-20 Minerva Biotechnologies Corporation Oligonucleotide identifiers

Similar Documents

Publication Publication Date Title
JP2003530432A5 (https=)
US10676472B2 (en) Crystal forms of glutaminase inhibitors
JP4212149B2 (ja) 医薬
JP2009536620A5 (https=)
JP2010509356A5 (https=)
JP2005519908A5 (https=)
JP2013530964A5 (https=)
JP2007519649A5 (https=)
JP2009515887A5 (https=)
JP2006502137A5 (https=)
WO2007093624A2 (en) Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin
EP2026783A2 (en) Method for enhancing cognitive function
JP2019511204A (ja) コパンリシブバイオマーカー
JP2009541387A5 (https=)
JP2007538031A5 (https=)
CN111479568A (zh) 司培前列素与Rho激酶抑制剂的组合药物
JP2020510061A5 (https=)
JP7493939B2 (ja) 関節リウマチの治療用組成物および治療方法
JPH02138214A (ja) 不安を治療する方法
JP2006510632A5 (https=)
CN103025722B (zh) 具有2-(杂芳基)氨基取代基的氯苯吩嗪及其抗微生物活性
AU2008257322B2 (en) Use of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of motor disorders related to Parkinson's disease
AU2012258339A1 (en) New combination between 4-{3-[Cis-Hexahydrocyclopenta[c]Pyrrol-2(1H)-yl]Propoxy}Benzamide and an NMDA receptor antagonist, and pharmaceutical compositions containing it
CN1859846A (zh) 白屈菜赤碱、其类似物及其在治疗躁郁症和其他认知紊乱中的应用
JP2005506324A5 (https=)